FDA and Compounding: A Risk-Based Regulatory Framework
This article was originally published in RPM Report
Executive Summary
FDA Commissioner Margaret Hamburg outlines an approach to address the practice of pharmacy compounding in response to an outbreak of fungal meningitis associated with a Massachusetts compounding pharmacy